Manufacture of basic pharmaceutical products
SCANDIDERMA AS
Revenue 2024
NOK 1.3m
Operating profit
NOK 1.1m
Equity
NOK −6.0m
Incorporated
2010
Share capital
NOK 241,000
Key figures · 2024
Current ratio
0.02
Equity ratio
-1440.7%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 87.1% | |
| Net margin (%%) | 96.2% | |
| Return on assets (%%) | 262.6% | |
| Likviditet | ||
| Current ratio | 0.02 | |
| Working capital | −1.3m | |
| Soliditet | ||
| Equity ratio (%%) | -1440.7% | |
| Debt-to-equity ratio | -1.07 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.